Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that it has priced a public offering of 4 million shares of common stock at $5.45 per share.

The offering is expected to bring in gross proceeds of $21.8 million and net proceeds of around $20.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.